Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
P/E ratio for Krystal Biotech, Inc. (KRYS)
P/E ratio as of 2023: 308.15
According to Krystal Biotech, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 308.15. At the end of 2022 the company had a P/E ratio of -14.43.
P/E ratio history for Krystal Biotech, Inc. from 2016 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 308.15 |
| 2022 | -14.43 |
| 2021 | -22.32 |
| 2020 | -35.04 |
| 2019 | -46.13 |
| 2018 | -21.38 |
| 2017 | -7.12 |
| 2016 | -39.56 |